$3500 | Single User
$7000 | Site License
$10500 | Enterprise License

Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Pipeline Review, H1 2017
[Lowest Price Guaranteed: $3,500]

Published by Global Markets Direct: 30 May 2017 | 75260 | In Stock

Introduction

Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Pipeline Review, H1 2017

Summary

Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Lysosomal Alpha Glucosidase - Pipeline Review, H1 2017, outlays comprehensive information on the Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Lysosomal alpha-glucosidase is an enzyme encoded by the GAA gene. It is essential for the degradation of glygogen to glucose in lysosomes. Defects in this gene lead to glycogen storage disease II or Pompe disease. The molecules developed by companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1, 7 and 2 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Pompe Disease.

Furthermore, this report also reviews key players involved in Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20)

- The report reviews Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20)targeted therapeutics and enlists all their major and minor projects

- The report assesses Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20)development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Pipeline Review, H1 2017

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Overview

    Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Companies Involved in Therapeutics Development

    Amicus Therapeutics Inc

    Audentes Therapeutics Inc

    Etubics Corp

    Genzyme Corp

    greenovation Biotech GmbH

    Huons Co Ltd

    JCR Pharmaceuticals Co Ltd

    Oxyrane Belgium NV

    Pharming Group NV

    Sarepta Therapeutics Inc

    Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Drug Profiles

    Antisense Oligonucleotide to Activate Lysosomal Alpha-Glucosidase for Pompe Disease - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AT-982 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ATB-200 + miglustat - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Gene Therapy 1 to Activate Acid Alpha-Glucosidase for Pompe Disease - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Gene Therapy 2 to Activate Acid Alpha-Glucosidase for Pompe Disease - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Gene Therapy to Activate Acid Alpha-Glucosidase for Pompe Disease - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Gene Therapy to Activate Acid Alpha-Glucosidase for Pompe Disease - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    GZ-402666 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    HU-023 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    JR-162 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    MOSS-GAA - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    OXY-2810 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    PGN-004 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Recombinant Alpha Glucosidase Replacement for Pompe Disease - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    VAL-1221 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Dormant Products

    Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Discontinued Products

    Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Product Development Milestones

    Featured News & Press Releases

    May 15, 2017: Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Pompe Phase 1/2 Study

    Mar 03, 2017: Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease

    Feb 15, 2017: Amicus Therapeutics Presents Important New Scientific Findings and Preclinical Data for Pompe Program at WORLDSymposium 2017

    Dec 08, 2016: Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study of Novel Treatment Paradigm for Pompe Disease

    Nov 17, 2016: Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease to Begin in the UK

    Nov 04, 2016: Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease

    Mar 03, 2016: Sanofi Genzyme Presents Results from Phase 1/2 Study of Investigational Second-Generation Therapy for Pompe Disease

    Mar 01, 2016: Amicus Therapeutics Highlights Preclinical Pompe Data at WORLDSymposium 2016

    Feb 10, 2016: Amicus Therapeutics Announces Oral and Poster Presentations on Chaperone AT2221 at 12th Annual WORLDSymposium 2016

    Jan 11, 2016: Amicus Therapeutics Provides Update On Novel ERT for Pompe Disease (ATB200 + Chaperone)

    Dec 22, 2015: Amicus Therapeutics Commences Phase 1/2 Study of Novel ERT for Treatment of Pompe Disease

    Sep 03, 2015: Valerion Therapeutics Announces Positive Results Of Non-Clinical Research Study at SSIEM Annual Symposium

    May 11, 2015: Audentes Therapeutics To Present New Data On AT-002 at American Society of Gene and Cell Therapy Annual Meeting

    Feb 10, 2015: Amicus Therapeutics Presents Preclinical Data on Next-Generation Pompe ERT at WORLD Symposium 2015

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

75260 | GMDHC0785TDB

Number of Pages

60

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Lysosomal Storage Disease Partnering 2010-2017
The Global Lysosomal Storage Disease Partnering Terms and Agreements since 2010 report provides unde...
01 Nov 2017 by Current Partnering USD $1,495 More Info
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Pipeline Review, H2 2017
Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Pipeline Rev...
31 Oct 2017 by Global Markets Direct USD $3,500 More Info
Global Lysosomal Storage Disease Partnering 2010-2017
The Global Lysosomal Storage Disease Partnering Terms and Agreements since 2010 report provides unde...
01 Oct 2017 by Current Partnering USD $1,495 More Info
Global Lysosomal Storage Disease Partnering 2010-2017
The Global Lysosomal Storage Disease Partnering Terms and Agreements since 2010 report provides unde...
01 Sep 2017 by Current Partnering USD $1,495 More Info
Lysosomal Storage Disorder-Pipeline Insights, 2017
DelveInsight’s, “ Lysosomal Storage Disorder-Pipeline Insights, 2017”, report provides in depth insi...
30 May 2017 by Delve Insight USD $1,250 More Info
Global Lysosomal Storage Disease Partnering 2010-2017
The Global Lysosomal Storage Disease Partnering Terms and Agreements since 2010 report provides unde...
01 Apr 2017 by Current Partnering USD $1,495 More Info
Global Lysosomal Storage Disease Partnering 2010-2017
The Global Lysosomal Storage Disease Partnering Terms and Agreements since 2010 report provides unde...
01 Feb 2017 by Current Partnering USD $1,495 More Info
Global Lysosomal Storage Disease Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Lysosomal Storage Disease Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Lysosomal Storage Disorder Global Clinical Trials Review, H2, 2015
Lysosomal Storage Disorder Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial...
23 Dec 2015 by Global Data USD $2,500 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Pipeline Review, H1 2017 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...